Gene test may guide breast cancer treatment decisions
NCT ID NCT06723990
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether a genetic test called HER2DX can help doctors decide on the best treatment for people with early-stage HER2-positive breast cancer. The study will enroll 60 patients and observe how often the test results change the treatment plan recommended by a team of specialists. The goal is to see if the test improves confidence in treatment choices, not to directly test a new drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HER2DX genetic test
What this could lead to
If successful, this could show that a genetic test helps doctors personalize treatment for HER2+ breast cancer, potentially improving outcomes and reducing unnecessary side effects.
What could go wrong
This is a small, observational study (60 people) at one center. It only measures if doctors change their decisions, not if those changes actually improve patient health. The test may not be widely adopted or beneficial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER EARLY STAGE BREAST CANCER (STAGE 1-3) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Istituto Europeo di Oncologia
RECRUITINGMilan, Italy, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••